Open experience with a new myorelaxant agent for low back pain

Advances in Therapy

Volumn 25, Issue 10, 2008, Pages 1010-1018

  Sartini, Silvana ^a   Guerra, Lucia ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Alfa Wassermann SpA   (Italy)

Author keywords

Analgesic; Eperisone hydrochloride; Low back pain; Muscle relaxant

Indexed keywords

CENTRAL MUSCLE RELAXANT; EPERISONE; PROPIOPHENONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LOW BACK PAIN; MALE; MIDDLE AGED; PAIN ASSESSMENT;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; PAIN MEASUREMENT; PROPIOPHENONES; YOUNG ADULT;

EID: 61749083037     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0108-9     Document Type: Article

References (36)

1. Reginster JY. The prevalence and burden of arthritis. Rheumatology. 2002;41 (suppl. 1):3-6.
2. Jackson KC 2nd. Pharmacotherapy in lower back pain. Drugs Today (Barc). 2004;40: 765-772. (Pubitemid 39482305)
3. Centers for Disease Control. Prevalence of disabilities and associated health conditions among adults-United States, 1999. MMWR Morb Mortal Wkly Rep. 2001;50:120-125.
4. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000 Summary. Advance Data Vital and Health Statistics; No. 328. Hyattsville, MD: National Center for Health Statistics; 2002.
5. Raspe H. Management of chronic low back pain in 2007-2008. Curr Opin Rheumatol. 2008;20:276-281. (Pubitemid 351483316)
6. Hernandez-Diaz S, Garcia Rodriguez LA. Epidemiological assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;110(suppl. 3A):20S-27S. (Pubitemid 32155399)
7. Garcia Rodriguez LA, Hernandez-Diaz S. The epidemiology of myocardial infarction and heart failure among users of nonsteroidal antiinflammatory drugs. Epidemiology. 2000;11:382-386.
8. Nielsen GL, Sorensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal antiinflammatory drugs: population-based observational study and case-control study. Brit Med J. 2001;322:266-270. (Pubitemid 32178552)
9. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12:570-576. (Pubitemid 32762000)
10. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo-and active-controlled phase III study. J Pain. 2005;6:21-28. (Pubitemid 40051998)
11. Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain. 1999;15:179-183. (Pubitemid 29467548)
12. Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manage. 1999;18:271-279. (Pubitemid 29469705)
13. Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol. 2000;27:772-778. (Pubitemid 30151361)
14. Ruoff GE, Rosenthal N, Jordan D, Karim R, Kamin M. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebocontrolled outpatient study. Clin Ther. 2003;25:1123-1141. (Pubitemid 36532582)
15. Elenbaas JK. Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980;37:1313-1323. (Pubitemid 11192105)
16. Morikawa K, Oshita M, Yamazaki M, et al. Pharmacological studies of the new centrally acting muscle relaxant 4'-ethyl-2-methyl-3- pyrrolidinopropiophenone hydrochloride. Arzneimittelforschung. 1987;37:331-336. (Pubitemid 17026259)
17. Matsunaga M, Uemura Y, Yonemoto Y, et al. Long-lasting muscle relaxant activity of eperisone hydrochloride after percutaneous administration in rats. Jpn J Pharmacol. 1997;73:215-220. (Pubitemid 27170660)
18. Iwase S, Mano T, Saito M, Ishida G. Effect of a centrally-acting muscle relaxant, eperisone hydrochloride, on muscle sympathetic nerve activity in humans. Funct Neurol. 1992;7:459-470. (Pubitemid 23062562)
19. Sakaue A, Honda M, Tanabe M, Ono H. Antinociceptive effects of sodium channelblocking agents on acute pain in mice. J Pharmacol Sci. 2004;95:181-188. (Pubitemid 38899687)
20. Farkas S. Silperisone: a centrally acting muscle relaxant. CNS Drug Rev. 2006;12:218-235. (Pubitemid 46047789)
21. Kocsis P, Farkas S, Fodor L, et al. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005;315:1237-1246. (Pubitemid 41635412)
22. Nakagawa M, Nakahara K, Maruyama Y, et al. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurovirol. 1996;2:345-355. (Pubitemid 26372460)
23. Murayama K, Katsumi T, Tajika E, Nakamura T. Clinical application of eperisone hydrochloride to neurogenic bladder. Hinyokika Kiyo. 1984;30:403-408. (Pubitemid 14106726)
24. Kobayashi Y, Kawasaki T, Yoshimi T, Nakajima T, Kanai K. Muscle cramps in chronic liver diseases and treatment with antispastic agent (eperisone hydrochloride). Dig Dis Sci. 1992;37:1145-1146.
25. Weinblatt ME. Nonsteroidal antiinflammatory drug toxicity: increased risk in the elderly. Scand J Rheumatol Suppl. 1991;91:9-17.
26. Bose K. The efficacy and safety of eperisone in patients with cervical spondylosis: results of a randomized, double-blind, placebocontrolled trial. Methods Find Exp Clin Pharmacol. 1999;21:209-213. (Pubitemid 29262305)
27. Tariq M, Akhtar N, Ali M, Rao S, Badshah M, Irshad M. Eperisone compared to physiotherapy on muscular tone of stroke patients: a prospective randomized open study. J Pak Med Assoc. 2005;55:202-204. (Pubitemid 41323228)
28. Snapinn SM. Evaluating the efficacy of a combination therapy. Stat Med. 1987;6:657-665.
29. Borenstein DG, Lacks S, Wiesel SW. Cyclobenzaprine and naproxen versus naproxen alone in the treatment of acute low back pain and muscle spasm. Clin Ther. 1990;12:125-131. (Pubitemid 20176184)
30. Graven-Nielsen T, Jansson Y, Segerdahl M, et al. Experimental pain by ischaemic contractions compared with pain by intramuscular infusions of adenosine and hypertonic saline. Eur J Pain. 2003;7:93-102. (Pubitemid 36142465)
31. Yabuki S, Kikuchi S, Midorikawa H, Hoshino S. Vascular backache and consideration of its pathomechanisms: report of two cases. J Spinal Disord. 1999;12:162-167. (Pubitemid 30263433)
32. Inoue S, Bian K, Okamura T, Okunishi H, Toda N. Mechanisms of action of eperisone on isolated dog saphenous arteries and veins. Jpn J Pharmacol. 1989;50:271-282. (Pubitemid 19169455)
33. Juni P, Nartey L, Reichenback S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative metaanalysis. Lancet. 2004;364:2021-2029. (Pubitemid 39593078)
34. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the Cochrane collaboration. Spine. 2003;28:1978-1992. (Pubitemid 37082665)
35. Chou R, Huffman LH. American Pain Society. American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med. 2007;147:505-514. (Pubitemid 351664521)
36. Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004;26:1355-1367. (Pubitemid 39572151)